痴呆与多病共存患者中的潜在不适当处方及其不良健康结局发生率
该回顾性队列研究基于英格兰初级保健电子健康记录与医院出院数据,纳入2016年11175例65岁以上痴呆患者及43463例年龄性别匹配对照,用STOPP V2标准定义潜在不适当处方(PIP)。痴呆组PIP发生率为73%,校正合并症后PIP风险仍升高(OR 1.92,CI 83-103%,P<0.01);随访1年内PIP与全因死亡、跌倒、压疮、贫血和骨质疏松风险增加相关。
要点
- 痴呆患者PIP发生率达73%,校正合并症后风险仍显著升高。
- PIP最常见于抗胆碱能药物和治疗重复。
- PIP与1年内全因死亡、跌倒、压疮、贫血和骨质疏松风险增加相关。
核心结论
- 痴呆患者常接受潜在不适当处方,且发生PIP者更易出现不良健康结局。
- 结果提示需优化痴呆患者用药,尤其合并症较多者。
研究设计与样本
- 回顾性队列研究,数据来自英格兰初级保健电子健康记录链接医院出院数据。
- 纳入2016年11175例65岁以上痴呆患者和43463例年龄性别匹配对照。
- 采用STOPP V2标准定义PIP,用logistic回归分析基线合并症关联,生存分析评估新发不良健康结局风险,校正年龄、性别、剥夺指数和14种合并症。
主要发现
- 痴呆组PIP发生率为73%,校正合并症后PIP风险升高(OR 1.92,CI 83-103%,P<0.01)。
- 最常见PIP标准涉及抗胆碱能药物和治疗重复。
- 合并冠心病(OR 2.17,CI 1.91-2.46,P<0.01)、严重精神疾病(OR 2.09,CI 1.62-2.70,P<0.01)和抑郁(OR 1.81,CI 1.62-2.01,P<0.01)者PIP风险更高。
- 随访1年内,PIP与全因死亡(HR 1.14,CI 1.02-1.26,P<0.02)、皮肤溃疡和压疮(HR 1.66,CI 1.12-2.46,P<0.01)、跌倒(HR 1.37,CI 1.15-1.63,P<0.01)、贫血(HR 1.61,CI 1.10-2.38,P<0.02)和骨质疏松(HR 1.62,CI 1.02-2.57,P<0.04)风险增加相关。
关键数值与推荐
- PIP定义采用Screening Tool of Older Persons' Prescriptions V2(STOPP V2)。
- 痴呆组PIP发生率为73%。
- 校正合并症后痴呆组PIP的OR为1.92(CI 83-103%,P<0.01)。
临床怎么用
- 对痴呆患者应常规筛查PIP,尤其关注抗胆碱能药物和治疗重复。
- 合并冠心病、严重精神疾病或抑郁的痴呆患者PIP风险更高,应优先优化用药。
- PIP与死亡、跌倒、压疮、贫血和骨质疏松风险增加相关,提示用药优化可能改善这些结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: treatment of dementia in individuals with comorbidities is complex, leading to potentially inappropriate prescribing (PIP). The impact of PIP in this population is unknown. OBJECTIVE: to estimate the rate of PIP and its effect on adverse health outcomes (AHO). DESIGN: retrospective cohort. SETTING: primary care electronic health records linked to hospital discharge data from England. SUBJECTS: 11,175 individuals with dementia aged over 65 years in 2016 and 43,463 age- and sex-matched controls. METHODS: Screening Tool of Older Persons' Prescriptions V2 defined PIP. Logistic regression tested associations with comorbidities at baseline, and survival analyses risk of incident AHO, adjusted for age, gender, deprivation and 14 comorbidities. RESULTS: the dementia group had increased risk of PIP (73% prevalence; odds ratio [OR]: 1.92; confidence interval [CI]: 83-103%; P < 0.01) after adjusting for comorbidities. Most frequent PIP criteria were related to anti-cholinergic drugs and therapeutic duplication. Risk of PIP was higher in patients also diagnosed with coronary-heart disease (odds OR: 2.17; CI: 1.91-2.46; P < 0.01), severe mental illness (OR: 2.09; CI: 1.62-2.70; P < 0.01); and depression (OR: 1.81; CI: 1.62-2.01; P < 0.01). During follow-up (1 year), PIP was associated with increased all-cause mortality (hazard ratio: 1.14; CI: 1.02-1.26; P < 0.02), skin ulcer and pressure sores (hazard ratio: 1.66; CI: 1.12-2.46; P < 0.01), falls (hazard ratio: 1.37; CI: 1.15-1.63; P < 0.01), anaemia (hazard ratio: 1.61; CI: 1.10-2.38; P < 0.02) and osteoporosis (hazard ratio: 1.62; CI: 1.02-2.57; P < 0.04). CONCLUSION: patients with dementia frequently receive PIPs, and those who do are more likely to experience AHO. These results highlight the need to optimise medication in dementia patients, especially those with comorbidities.
引用
- Delgado J, Jones L, Bradley MC, et al. Potentially inappropriate prescribing in dementia, multi-morbidity and incidence of adverse health outcomes. Age Ageing. 2021. PMID: 32946561. doi:10.1093/ageing/afaa147
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。